Clinical Trial Update: Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenvatinib plus denosumab for predominantly bone metastatic radioiodine-refractory differentiated thyroid carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Thyroid Cancer Metastasis

Drugs mentioned

• Denosumab (denosumab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Thyroid Cancer Metastatic | Phase 2 | Status: UNKNOWN